Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Dermavant Sciences

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: DMVT-505

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            The publication highlighted the secondary efficacy and patient-reported outcomes from its Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2020

            Details:

            The long-term safety study is part of a Phase 3 program for Tapinarof, which also includes Psoaring 1 and Psoaring 2, two identical Phase 3 clinical trials to evaluate the efficacy and safety of Tapinarof in adult patients with Plaque Psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2020

            Details:

            A significantly higher proportion of patients treated with tapinarof 1% QD reported very or moderately improved psoriasis symptoms and psoriasis-related pruritus compared with those receiving vehicle QD at Week 12.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2020

            Details:

            Psoaring 1 and Psoaring 2 are two identical phase 3 clinical trials that have enrolled a combined 1,025 patients to evaluate the safety and efficacy of tapinarof in adults with plaque psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Japan Tobacco

            Deal Size: $113.0 million Upfront Cash: $60.0 million

            Deal Type: Licensing Agreement January 15, 2020

            Details:

            A license agreement to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis.